U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Malignant Mesothelioma

MedGen UID:
1659783
•Concept ID:
C4725811
•
Neoplastic Process

Definition

Malignant mesothelioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Malignant Mesothelioma

Professional guidelines

PubMed

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
Favoni RE, Daga A, Malatesta P, Florio T
Br J Pharmacol 2012 May;166(2):532-53. doi: 10.1111/j.1476-5381.2012.01873.x. PMID: 22289125Free PMC Article
Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW
Int J Cancer 2010 Jun 15;126(12):2762-72. doi: 10.1002/ijc.25202. PMID: 20104527

Recent clinical studies

Etiology

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299

Therapy

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793Free PMC Article
Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.
Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE
J Interferon Res 1990 Oct;10(5):531-4. doi: 10.1089/jir.1990.10.531. PMID: 2273299

Prognosis

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
Calabrò L, Ceresoli GL, di Pietro A, Cutaia O, Morra A, Ibrahim R, Maio M
Cancer Immunol Immunother 2015 Jan;64(1):105-12. Epub 2014 Sep 19 doi: 10.1007/s00262-014-1609-9. PMID: 25233793Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...